Bial SA, of S. Mamede do Coronado, Portugal, and Tokyo-based Eisai Co. Ltd. reported data from their study 208 phase II trial testing Zebinix (eslicarbazepine acetate) in children ages 6-16 years old with focal-onset epilepsy at the 12th European Paediatric Neurology Society Congress in Lyon, France.